Prostate Cancer

>

Latest News

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
Darolutamide/ADT Improves rPFS in Metastatic HSPC

October 13th 2024

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

October 11th 2024

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC

October 10th 2024

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

October 4th 2024

In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.
Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer

September 30th 2024